MBRXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses...

Stats
本日の出来高	34 317.00
平均出来高	111 403
時価総額	11.20M
EPS	$0 ( 2024-03-27 )
次の収益日	( $-3.59 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.330
ATR14	$0.0820 (1.63%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-26	Foster Jonathan P.	Buy	28 986	Common Stock
2023-12-26	George Robert E.	Buy	14 493	Common Stock
2023-12-26	Klemp Walter V	Buy	188 404	Common Stock
2023-07-11	Klemp Walter V	Sell	13 204	Restricted Stock Units
2023-07-11	Klemp Walter V	Buy	13 204	Common Stock

INSIDER POWER
83.04
Last 98 transactions
Buy: 6 351 373 \| Sell: 471 392

Moleculin Biotech Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Moleculin Biotech Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2023
収益:	$0
総利益:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2022
収益:	$0
総利益:	$-222 000 (0.00 %)
EPS:	$-14.37

FY	2021
収益:	$0.00
総利益:	$-164 000 (0.00 %)
EPS:	$-1.614

Financial Reports:

No articles found.

Moleculin Biotech Inc

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.